Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure
Journal of the American College of Cardiology · 2023
DOI: 10.1016/j.jacc.2023.02.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American College of Cardiology, 2023. Verfasst von Safia Chatur und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/sa…. Hauptthemen laut MEDLINE: Tetrazoles, Heart Failure. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown. OBJECTIVES: This investigation aimed to evaluate the association between the occurrence of moderate estimated glomerular filtration rate (eGFR) decline (>15%) after initial exposure to sacubitril/valsartan and subsequent cardiovascular outcomes and its treatment benefits in PARADIGM-HF and PARAGON-HF. METHODS: In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF). RESULTS: Among randomized participants, 11% in PARADIGM-HF and 10% in PARAGON-HF experienced eGFR decline (>15%) during sacubitril/valsartan run-in. eGFR partially recovered (from nadir to postrandomization week 16) regardless of sacubitril/valsartan continuation or switch to renin-angiotensin system inhibitor (RASi) postrandomization. Initial eGFR decline was not consistently associated with clinical outcomes in either trial. Treatment benefits of sacubitril/valsartan vs RASi on primary outcomes were similar irrespective of run-in eGFR decline in PARADIGM-HF (eGFR decline, HR: 0.69; 95% CI: 0.53-0.90; and no eGFR decline, HR: 0.80; 95% CI: 0.73-0.88; Pinteraction = 0.32) and PARAGON-HF (eGFR decline, rate ratio [RR]: 0.84; 95% CI: 0.52-1.36 and no eGFR decline, RR: 0.87; 95% CI: 0.75-1.02, Pinteraction = 0.92). The treatment effect of sacubitril/valsartan remained consistent across a range of eGFR declines. CONCLUSIONS: Moderate eGFR decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained in heart failure across a broad range of eGFR declines. Early eGFR changes should not deter continuation of sacubitril/valsartan or stall uptitration. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitors with Angiotensin-Converting Enzyme Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/safchat.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada.
- Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina, USA.
- Baylor University Medical Center, Dallas, Texas, USA.
Zitieren
APA
Chatur, S., Claggett, B. L., McCausland, F. R., Rouleau, J., Zile, M. R., Packer, M., Pfeffer, M. A., Lefkowitz, M., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2023). Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2023.02.009
Vancouver
Chatur S, Claggett BL, McCausland FR, Rouleau J, Zile MR, Packer M, et al. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure. Journal of the American College of Cardiology. 2023. doi:10.1016/j.jacc.2023.02.009
BibTeX
@article{Chatur2023,
author = {Chatur, Safia and Claggett, Brian L and McCausland, Finnian R and Rouleau, Jean and Zile, Michael R and Packer, Milton and Pfeffer, Marc A and Lefkowitz, Martin and McMurray, John J V and Solomon, Scott D and Vaduganathan, Muthiah},
title = {Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure},
journal = {Journal of the American College of Cardiology},
year = {2023},
doi = {10.1016/j.jacc.2023.02.009}
}
EUVIMED